Herantis Publishes Year-End Report for 2021
Herantis Pharma Plc, Company Release, inside information, 3 March 2022 at 08:00 EET “An important milestone for Herantis in 2021 was the selection of HER-096, a synthetic, small peptidomimetic, as the lead preclinical development candidate for the treatment of Parkinson’s disease. This was done by a rigorous process based on extensive preclinical and CMC-data. During 2021 we also validated HER-096’s unique mechanism of action, its passage into the brain in therapeutic concentrations upon simple subcutaneous administration and the efficacy of a convenient three times per week dosing